

## Anti-CTLA-4/CD152 Antibody (Tremelimumab)

### Introduction

Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T lymphocyte antigen 4 (CTLA-4) for use in metastatic melanoma research.

### Product parameters

Alternative Names	ticilimumab, CP-675206, clone 11.2.1
Target Accession	P16410
Target	CTLA-4 / CD152
CAS number	745013-59-6
Molecular Weight	146.38 kDa
Host	CHO
Reactivity	Human, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human CTLA 4 His at 2 ug/mL can bind Anti-CTLA-4/CD152 Antibody (Tremelimumab), EC50=0.004377 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

